Fig. 4

R2M3-26 improves lung function and histology in a two-hit acute bleomycin model. (A) Study design showing two-hit bleomycin administration and bi-weekly molecule doses with termination at day 28. Figure legend applies to all graphs, Saline (uninjured), Anti-GFP (30 mpk), R2M3-26 (30 mpk). (B) Bodyweight in grams. (C-G) Measurements of lung function. (H) Ratio of lung weight to bodyweight at termination on day 28. (I) Soluble collagen at day 28. (J-L) Histopathology assessments. (M) Representative IF images showing complete section scans (left column); the three right columns show higher magnification views of the inset box on the left as follows: ACTA2 IF signal, pseudo-colored positive signal levels, and combined ACTA2, SFTPC, and RAGE/AGER IF expression. Each row represents the indicated treatment. (N) Percentage of ACTA2 IF signal area to tissue area. (O) Average mRNA expression of the Fzd and Lrp Wnt receptors in mouse scRNA-seq data by cell type from Strunz et al., 2020. (P) Average mRNA expression of FZD and LRP in human scRNA-seq data by cell type from Haberman et al., 2020. (Q) Axin2 expression in the lungs in the acute bleomycin model, assessed by RT-qPCR at the indicated timepoints after a single treatment. (R) Representative images of Axin2 mRNA and SFTPC protein expression at 8 h after a single dose of the indicated treatment; DAPI was used to label nuclei; scale bar = 100 μm. Error bars represent SEM; * p value < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001